ADOPTIVE TRANSFER OF EX-VIVO ACTIVATED MEMORY T-CELLS WITH OR WITHOUT CYCLOPHOSPHAMIDE FOR ADVANCED METASTATIC MELANOMA - RESULTS IN 36 PATIENTS

被引:13
作者
GOLD, JE
ROSS, SD
KRELLENSTEIN, DJ
LAROSA, F
MALAMUD, SC
OSBAND, ME
机构
[1] MT SINAI HOSP,DEPT CARDIOTHORAC SURG,NEW YORK,NY 10029
[2] CUNY MT SINAI SCH MED,NEW YORK,NY 10029
[3] ALBERT EINSTEIN COLL MED,BETH ISRAEL MED CTR,DEPT MED,DIV HEMATOL ONCOL,NEW YORK,NY
[4] BOSTON CITY HOSP,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,BOSTON,MA 02118
[5] BOSTON UNIV,SCH MED,BOSTON,MA 02118
[6] CELLCOR,NEWTON,MA
[7] ODYSSEY THERAPEUT,CAMBRIDGE,MA
关键词
IMMUNOTHERAPY; ADOPTIVE; MELANOMA; T-CELL; MEMORY;
D O I
10.1016/0959-8049(94)00523-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Autolymphocyte therapy (ALT) is the infusion of autologous peripheral blood mononuclear cells (PBMC) activated ex vivo by a cytokine-rich supernatant (T3CS) generated from a previous autologous lymphocyte culture using low doses of the anti-CD3 mitogenic monoclonal antibody. The mechanism of action is enhancement of a recall response by CD45RO(+) (memory) T-cells (ALT cells) to host tumour without dependence on exogenous interleukin (IL)-2. The existence of anti-tumour-specific T-cells in melanoma patients has been well described, and efforts to utilise them therapeutically have achieved modest tumour response rates. However, few long-term survival data have been reported. From 1986 to 1992, we treated 36 patients with disseminated melanoma using ALT alone (26 patients) or adoptive chemoimmunotherapy using ALT and cyclophosphamide (CY) (10 patients). Over this time period, the cell activation method evolved from using cytokine supernatants derived from a one-way allogeneic mixed lymphocyte culture (MLCS), to the current practice of utilising anti-CD3 and autologous cytokines (T3CS). There were 21 men and 15 women, average age 57 years, range 30-82. 27 had failed prior therapies and 9 had no prior therapy. A total of 161 infusion of ALT cells were given: 65 with cells activated in MLCS and 96 with T3CS. There were no grade 3 adverse events, and an approximate 20% incidence of grades 1 and 2 reactions to ALT-cell infusions. Transient cytopenias were seen in patients receiving CY. Sixty-one per cent (22/36) of patients received the planned six ALT-cell infusions, while 39% did not due to progressive disease. In 33 evaluable patients, there were four complete responses, four partial responses and 6 patients with stable disease (SD). Responding patients and those with SD had prolonged survival compared to historical controls when matched for number of organ systems involved. Ex vivo depletion of CD45RO(+) T-cells revealed preferential lysis of autologous and HLA-A-matched melanoma targets that was dependent on these memory T-cells. These data suggest that adoptive cellular therapy using ex vivo activated memory T-cells with and without CY is active, has low toxicity, is tumour-specific and can result in clinical benefit in patients with disseminated melanoma.
引用
收藏
页码:698 / 708
页数:11
相关论文
共 59 条
[1]   LYSIS OF AUTOLOGOUS MELANOMA-CELLS BY TUMOR-INFILTRATING LYMPHOCYTES - ASSOCIATION WITH CLINICAL-RESPONSE [J].
AEBERSOLD, P ;
HYATT, C ;
JOHNSON, S ;
HINES, K ;
KORCAK, L ;
SANDERS, M ;
LOTZE, M ;
TOPALIAN, S ;
YANG, J ;
ROSENBERG, SA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1991, 83 (13) :932-937
[2]   TIL FROM RENAL-CELL CARCINOMA - RESTIMULATION WITH TUMOR INFLUENCES PROLIFERATION AND CYTOLYTIC ACTIVITY [J].
ALEXANDER, J ;
RAYMAN, P ;
EDINGER, M ;
CONNELLY, R ;
TUBBS, R ;
BUKOWSKI, R ;
PONTES, E ;
FINKE, J .
INTERNATIONAL JOURNAL OF CANCER, 1990, 45 (01) :119-124
[3]   T-CELL TUMOR ELIMINATION AS A RESULT OF T-CELL RECEPTOR MEDIATED ACTIVATION [J].
ASHWELL, JD ;
LONGO, DL ;
BRIDGES, SH .
SCIENCE, 1987, 237 (4810) :61-64
[4]  
BALCH CM, 1990, ARCH SURG-CHICAGO, V125, P200
[5]   A MULTIFACTORIAL ANALYSIS OF MELANOMA .4. PROGNOSTIC FACTORS IN 200 MELANOMA PATIENTS WITH DISTANT METASTASES (STAGE III) [J].
BALCH, CM ;
SOONG, SJ ;
MURAD, TM ;
SMITH, JW ;
MADDOX, WA ;
DURANT, JR .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (02) :126-134
[6]  
BERD D, 1988, CANCER RES, V48, P1671
[7]  
BOOKMAN MA, 1987, J IMMUNOL, V139, P3166
[8]   INHIBITION OF ESTABLISHED TRANSPLANTS OF CHEMICALLY INDUCED SARCOMAS IN SYNGENEIC MICE BY LYMPHOCYTES FROM IMMUNIZED DONORS [J].
BORBERG, H ;
BEATTIE, EJ ;
CHOUDRY, K ;
OETTGEN, HF .
INTERNATIONAL JOURNAL OF CANCER, 1972, 10 (03) :539-&
[9]  
BUKOWSKI RM, 1991, CANCER RES, V51, P4199
[10]  
CHEN Q, 1994, CANC IMMUNOL IMMUNOL, V34, P385